Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across immunology, oncology, neuroscience, and aesthetics. Through continued momentum of next-generation immunology brands, expansion in oncology, and disciplined lifecycle management, AbbVie reinforced its strategy to replace legacy revenue with durable, high-margin growth platforms.
Immunology Portfolio: Rebuilding the Growth Engine
SKYRIZI® — Autoimmune Diseases
Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
In 2025, SKYRIZI emerged as AbbVie’s largest growth driver, supported by expanded gastrointestinal indications and strong uptake across dermatology and rheumatology.
Strategic Impact:
SKYRIZI is positioned as a multi-indication blockbuster with long patent protection, anchoring AbbVie’s immunology leadership well into the 2030s.
RINVOQ® — Immune-Mediated Inflammatory Diseases
Conditions: Rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease
RINVOQ continued to expand its footprint in 2025, supported by new approvals, broader reimbursement, and increasing physician familiarity.
Strategic Impact:
Together, SKYRIZI and RINVOQ form AbbVie’s next-generation immunology duo, structurally replacing Humira-era revenues.
Oncology Portfolio: Hematologic Strength and Pipeline Expansion
IMBRUVICA® — Blood Cancers
Conditions: Chronic lymphocytic leukemia and other B-cell malignancies
Despite increased competition, IMBRUVICA remained a meaningful contributor in 2025, supported by earlier-line use and global markets.
Strategic Impact:
Established oncology brands continue to provide cash flow stability while AbbVie advances next-wave assets.
EPCORITAMAB — B-Cell Lymphomas
Condition: Relapsed or refractory diffuse large B-cell lymphoma
AbbVie progressed epcoritamab, a subcutaneous bispecific antibody, through regulatory and commercial expansion efforts in 2025, strengthening its presence in next-generation oncology modalities.
Strategic Impact:
Bispecific antibodies position AbbVie for future oncology growth with differentiated delivery and efficacy profiles.
Neuroscience Portfolio: Durable CNS Franchises
Vraylar® — Psychiatry
Conditions: Schizophrenia, bipolar disorder, major depressive disorder
Vraylar continued to show strong performance in 2025, supported by sustained demand and expanded awareness in depressive disorders.
Strategic Impact:
Neuroscience brands provide long-duration revenue streams with strong prescriber loyalty.
QULIPTA® / UBRELVY® — Migraine
Condition: Acute and preventive migraine treatment
AbbVie strengthened its migraine franchise in 2025, leveraging dual positioning across acute and preventive care.
Strategic Impact:
Migraine remains a high-growth CNS market, supporting AbbVie’s diversification strategy.
Aesthetics Portfolio: Resilient Consumer-Driven Growth
BOTOX® and JUVÉDERM®
Conditions: Medical aesthetics and therapeutic indications
AbbVie’s aesthetics business demonstrated resilience in 2025 despite macroeconomic pressure, supported by brand strength and global reach.
Strategic Impact:
Aesthetics provide non-reimbursed, cash-pay revenue streams, reducing exposure to pricing and reimbursement volatility.
Digital and AI-Enabled R&D
In 2025, AbbVie expanded its use of AI and advanced analytics to:
- Optimize clinical trial design
- Improve patient stratification in immunology and oncology
- Enhance lifecycle management and commercial planning
Strategic Impact:
Data-driven R&D is expected to improve development efficiency and portfolio decision-making in 2026 and beyond.
Looking Ahead: 2026 and Beyond
AbbVie enters 2026 with:
- A fully re-engineered immunology franchise
- Growing exposure to next-generation oncology
- Strong cash flow supporting continued investment and shareholder returns
The company’s 2025 execution demonstrates that the post-Humira era is increasingly defined by diversification, not decline.
Conclusion
AbbVie’s 2025 performance reflects a successful strategic transition, driven by blockbuster immunology brands, expanding oncology innovation, and resilient aesthetics revenue. With strong execution and pipeline depth, AbbVie is positioned to sustain growth and value creation well beyond 2026.
By